What's in NYU Langone Health's pipeline?

NYU Langone Health has 85 drugs in our index: 45 marketed, 0 filed, 8 in Phase 3, 22 in Phase 2, 9 in Phase 1.

Which companies overlap with NYU Langone Health's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Merck Sharp & Dohme LLC, Assistance Publique - Hôpitaux de Paris, Massachusetts General Hospital, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nyu-langone-health.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

NYU Langone Health — Portfolio Competitive Intelligence Brief

NYU Langone Health pipeline: 45 marketed, 0 filed, 8 Phase 3, 22 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

45 marketed 0 filed 8 Phase 3 22 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
DR SSB	DR SSB	marketed
Extended-Release Buprenorphine Injection	Extended-Release Buprenorphine Injection	marketed
XR-B (SUBLOCADETM)	XR-B (SUBLOCADETM)	marketed	Opioid agonist (buprenorphine)	Mu-opioid receptor (partial agonist)	Psychiatry / Addiction Medicine
CpG-adjuvanted HBV Vaccine	CpG-adjuvanted HBV Vaccine	marketed
Anti-ADHD medication	Anti-ADHD medication	marketed
Topical Preparation H arm	Topical Preparation H arm	marketed
DR OnQ	DR OnQ	marketed
Lidocaine Hydrochloride with Epinephrine	Lidocaine Hydrochloride with Epinephrine	marketed
Evolocumab Cartridge	Evolocumab Cartridge	marketed
Blood laboratory tests	Blood laboratory tests	marketed
Bupivacaine (Marcaine)	Bupivacaine (Marcaine)	marketed	Local anesthetic (amide)	Voltage-gated sodium channels	Anesthesia
Palonosetron with Dexamethasone	Palonosetron with Dexamethasone	marketed

Therapeutic area mix

Other · 5
Cardiovascular · 5
Neurology · 2
Psychiatry / Addiction Medicine · 2
Oncology · 2
Psychiatry / Mental Health · 2
Immunology · 2
Anesthesiology · 1
Addiction Medicine / Smoking Cessation · 1
General Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 7 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
Assistance Publique - Hôpitaux de Paris · 5 shared drug classes
Massachusetts General Hospital · 4 shared drug classes
Pfizer · 4 shared drug classes
Beijing Tiantan Hospital · 3 shared drug classes
Ain Shams University · 3 shared drug classes
Icahn School of Medicine at Mount Sinai · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for NYU Langone Health:

Cite this brief

Drug Landscape (2026). NYU Langone Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nyu-langone-health. Accessed 2026-05-16.